Evaluation of One Burr Hole Evacuation for Subdural Hematoma

Status Not yet recruiting

Clinical Trial Summary

To evaluate the outcome of one burrhole evacuation for subdural hematoma and it has the same result of traditional two burrhole

Clinical Trial Description

- Subdural hematoma (SDH): abnormal Collection of Liquefied blood degradation underneath the dura matter (1.2.3). - one of the most frequent types of intracranial haemorrhage, That is still associated with significant morbidity (1.4.5). - The SDH: is a common disease in elderly Patient, and Its Incidence is highest in persons older than 70 Years of age (1.5). - Types of Subdural hematoma(18.19) 1- Acute: present within 48-72 hours of injury. 2. Sub-acute: manifest itself between 3-20 day. 3- Chronic (CH): produce symptoms from 3 weeks to several months after injury Risk Factors: (7.8.9.10.11.12) 1. Trauma; mostly minor Trauma, Approximately two thirds of The Patients have suffered one. Reports exist of chronic SDH due to birth trauma in neonates. 2. Advanced age: The elderly are at risk due to: 1. brain atrophy, whereby The bridging veins are stretched and become more fragile. 2. Older People tend to fall more often and Suffer minor head trauma. 3. With increase age, The incidence of blood Thinner administration raises leading to increased risk for haemorrhage 3. Chronic alcoholism: 4. Gender: men, from all age groups, suffer higher rates of chsDH than woman. 5. CoagulaPathy: Therapeutic anticoagulation and antiplatelet therapy. 6. Medical Conditions: sepsis, hepatic failure, hemophilia, DIC and renal dialysis. 7. Intracranial hypotension: as after ventriculoperitoneal shunt. clinical presentation (1.13) - Symptoms of increase intra cranial pressure: Headache, Nausea, vomiting. - Focal neurological deficit - (weakness, aphasia). - Disturbed conscious level (DCL) - Seizures - Imaging investigation: CT brain (14.15) - Management : (1.6.16.17) 1. Conservative: A watch, wait and re-scan Policy is usually recommended in asymptomatic or minimally symptomatic patient with a thin CHSDH. 2. Surgical: For symptomatic (SDH) a- burr hole drainage B-twist drill drainage c- craniotomy - prognostic factors : (2.5) 1- age of patient 2- Associated chronic diseases like hypertension, liver diseases …….Etc 3- Laboratory investigation like Hb , platlate count ,pc,and PT. 5- Hematoma thickness 6- number of burr hole : one or two burr hole ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06119932
Study type	Observational
Source	Assiut University
Contact	Mohammed Lotfi, Resident
Phone	01147341661
Email	Mohammedlotfi029@gmail.com
Status	Not yet recruiting
Phase
Start date	November 1, 2023
Completion date	October 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04402632` - Embolization of the Middle Meningeal Artery With ONYX™ Liquid Embolic System for Subacute and Chronic Subdural Hematoma	N/A
Completed	`NCT03496545` - Efficacy of Bromocriptine For Fever Reduction in Acute Neurologic Injury	Phase 1/Phase 2
Terminated	`NCT05472766` - Anticoagulation Therapy Timing in Atrial Fibrillation After Acute and Chronic Subdural Hematoma	N/A
Not yet recruiting	`NCT06052124` - Augmented Reality for Subdural Drain Placement	N/A
Completed	`NCT02368366` - Comparative Effectiveness of Family Problem-Solving Therapy (F-PST) for Adolescent TBI	N/A
Terminated	`NCT01463878` - Enteral Nutrition and Glycemic Variability Neurological Intensive Care Unit Study	Phase 4
Completed	`NCT02618382` - A Study on the Safety of Tranexamic Acid for the Chronic Subdural Hematoma Population	Phase 4
Recruiting	`NCT04923984` - Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada (EMMA Can)	N/A
Completed	`NCT03153150` - Start or STop Anticoagulants Randomised Trial (SoSTART)	Phase 3
Completed	`NCT04270955` - Dartmouth Middle Meningeal Embolization Trial (DaMMET)	N/A
Recruiting	`NCT06067750` - Comparison of Narcotrend and Cerebral Function Analysing Monitor in Intensive Care to Monitor Seizures and Deep Sedation
Not yet recruiting	`NCT05713630` - The Use of Tranexamic Acid in the Treatment of Symptomatic Subdural Hematoma	Phase 3
Withdrawn	`NCT01605357` - Hypernatremia for the Prevention and Treatment of Cerebral Edema in Traumatic Brain Injury	Phase 1/Phase 2
Withdrawn	`NCT04500795` - Prospective Study on the Use of Middle Meningeal Artery Embolization for Chronic Subdural Haematoma	N/A
Recruiting	`NCT04170582` - Patient Registry for Patients With Chronic Subdural Hematoma
Recruiting	`NCT05649904` - AFFECT Study for Patients With Intraventricular Hemorrhage, Subarachnoid Hemorrhage, Subdural Hematoma, and Ventriculitis	N/A
Recruiting	`NCT04211233` - Diagnostic Subdural EEG-electrode And Subdural hEmatoma (DISEASE)	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.